Curtis A. Lachowiez

Hematology

3181 SW Sam Jackson Park Rd
Portland, OR 97239

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 02, 2026

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

Journal: Blood

Published: May 04, 2026

Models, Models, Everywhere: But Which One Should Guide Care?

Models, Models, Everywhere: But Which One Should Guide Care?

Journal: Blood cancer discovery

Published: March 12, 2026

HMA+VEN triplet regimens for the initial treatment of AML in adults (PRO).

HMA+VEN triplet regimens for the initial treatment of AML in adults (PRO).

Journal: Blood advances

Published: February 04, 2026

A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard Therapies.

A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard Therapies.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Olutasidenib: an Achilles' heel for IDH1-mutated MDS?

Olutasidenib: an Achilles' heel for IDH1-mutated MDS?

Journal: Blood advances

Published: October 20, 2025

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.

Journal: Blood cancer journal

Published: October 05, 2025

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 12, 2025

Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy.

Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy.

Journal: JCO oncology practice

Published: May 09, 2025

Ivosidenib or venetoclax combined with hypomethylating agents in IDH1-mutated acute myeloid leukemia: a real-world study.

Ivosidenib or venetoclax combined with hypomethylating agents in IDH1-mutated acute myeloid leukemia: a real-world study.

Journal: Blood neoplasia

Published: February 24, 2025

Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.

Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.

Journal: Blood cancer discovery

Published: January 29, 2025

Showing 1-12 of 47

Last Updated: 09/26/2026